MD&A · 2025
In this section4 topics
Overview of Operations
Overview of Operations
Overall, Thailand's pharmaceutical and healthcare industry is expected to grow steadily. The industry's average growth rate in 2025 was approximately 8% (Source: IQVIA), driven by various factors that positively impacted BLC Group. Firstly, these include the growth of the aging population and the rise in non-communicable diseases (NCDs). Secondly, increased health risks from pollution and changing climate conditions supported the overall demand for medicines. Additionally, government policies encouraging healthcare access through pharmacy networks and the use of herbal medicine have made medicines and medical supplies more accessible to patients. Finally, the National Health Security Office (NHSO) now allows patients to receive medication from pharmacies without the need for a diagnosis for minor ailments, thereby expanding product reach and ensuring more comprehensive access.
However, the industry faces pressure from several challenges, including flooding in Southern Thailand, which has temporarily disrupted product distribution and purchasing power. Additionally, fluctuations in international tourist arrivals have affected sales from foreign patient segments in hospitals (Source: Ministry of Tourism and Sports), while prolonged geopolitical tensions continue to weigh on the economy. In response to these conditions, the Group remains committed to proactive marketing strategies and risk management to maintain its competitive edge and ensure sustainable growth.
For the future operational direction, the Group continues to target continuous growth by focusing on utilizing completed assets under construction to expand production capacity. This includes realizing benefits from energy cost reductions through the Solar Farm Project Phase 2, as well as tax privileges (BOI) from the new production facility, which will help enhance profitability and elevate operational efficiency. Furthermore, the Group will continue to pursue aggressive marketing strategies for high-margin product groups, while prioritizing working capital management and maintaining financial discipline to create good and sustainable returns for shareholders amidst economic volatility.
Operating Results & Financial Condition
Operating Results & Profitability
The Group’s revenue from sales and rendering services for the year ended December 31, 2025, was 1,667.5 million baht, representing an increase of 110.5 million baht, or 7.1%, compared to the previous year. This growth aligns with the overall pharmaceutical and healthcare industry, driven by effectively enhanced brand awareness and expanded competitive capabilities across both offline and online channels. These efforts included advertising, promotional campaigns featuring the use of presenters, and product exhibitions to directly reach customer groups. Moreover, the continuous expansion of business partnerships and the launch of new products that address market needs were also key drivers in growing the revenue base and increasing sales volumes across various product groups.
Generic drugs and new generic drugs: In 2025, the Group’s revenue from generic and new generic drugs increased by 4.2% compared to the previous year. This growth reflects the success in the continuous expansion of distribution channels, particularly from the Diabederm, Gastro Bismol, Spasium and Precius brands, which continue to gain consumer confidence. In addition, shifting consumer behavior toward increased health-consciousness, along with the government policies promoting easier access to pharmaceuticals, have been positive factors driving stable growth in demand for the Company’s products.
Cosmetics: Revenue from the cosmetics product segment in 2025 grew significantly by 32.1% year-on-year (YoY). This growth was primarily driven by the continued promotion of Clena Ex through online channels and collaboration with Key Opinion Leaders (KOLs) to raise brand awareness. This resulted in a significant increase in Clena Ex sales exceeding 60 million baht and was the highest revenue contributor to sales growth in the cosmetics segment. Furthermore, new products under the ‘B Zkin’ brand were launched during the year to meet diverse consumer needs.
Herbal medicines: Revenue from the herbal medicine product segment grew by 1.5% year-on-year (YoY) in 2025. This growth was driven by rising demand for medications and is attributable to recent government policies, media advertising, expanding distribution channels, and intensified online promotional activities focused on core brands like Plaivana and Capsika. The endorsement by a presenter, launched in the second quarter of 2025, also boosted Plaivana's brand awareness, despite temporary procurement delays for certain products within the hospital segment. Additionally, the introduction of a new product line under the Clenine, Plaivana Spray and cough syrup under the VitaCof brand during the year.
Food supplements: Revenue from the food supplement segment increased by 24.2% year-over-year (YoY) in 2025. This growth was primarily driven by the increased accessibility of Deeday and Prozeus products to drugstore customers, coupled with the launch of new products under the Deeday and Prozeus brands during the year such as Bio C, Multivitamin, Biotin and Prozeus Pink. Furthermore, several new products were introduced to the market, such as food supplements under the Baidy, Banago and Biotic-F brands, which served as another key factor in boosting sales growth.
Animal products: In 2025, revenue from the animal product segment declined by 42.1% compared to the previous year (YoY). This was primarily due to the ongoing risk from livestock disease outbreaks, which have directly impacted the demand for agricultural pharmaceuticals. In response, the Company diversified its exposure by expanding into the non-drug segment, including pet treats and supplements. Launched at the beginning of 2025, these initiatives aim to capture the rising momentum in the pet market.
Medical devices and others: This segment, which includes silicone gel for scar treatment, medical lubricants, mosquito repellent spray, and wound care supplies, grew by 15.0% in 2025 compared to last year. The growth was mainly driven by media advertising and marketing efforts, as well as the redesign of scar treatment product packaging to improve brand clarity and appeal.
Liquidity & Capital Adequacy
Liquidity Ratios: As at December 31, 2025, the current ratio and quick ratio, standing at 2.0 times and 1.0 times, respectively, representing a decrease from the end of 2024. This was primarily due to cash payments for investments in the construction of a new production plant and the acquisition of machinery during the year, coupled with an increase in inventories due to distribution constraints toward the end of the year, this resulted in a longer cash conversion cycle compared to the previous year.
Asset Management Capability
Assets
As of December 31, 2025, the Group’s total assets amounted to 2,365.6 million baht, representing an increase of 128.0 million baht from the end of 2024. This was primarily attributable to a decrease in current assets of 534.8 million baht, offset by a 662.8 million baht increase in non-current assets, as detailed below:
Cash and cash equivalents and Short-term investments decreased by 605.7 million baht from the end of 2024, mainly due to dividend payments, loan repayments to financial institutions and capital expenditures for investments in a new production plant and machinery during the year.
Trade receivables decreased by 13.1 million baht from the end of 2024, mainly due to a decrease in revenue for the Group during the fourth quarter of 2025 compared to the last quarter of 2024 (the normal credit term granted by the Group ranges from 30 days to 150 days). As at December 31, 2025, the Group recognized allowance for expected credit loss of 1.2 million baht. Overdue receivables accounted for 7.2% of total trade receivables (December 31, 2024: the allowance for expected credit loss was 1.1 million baht, and overdue receivables accounted for 4.6% of total receivables).
Inventories increased by 83.0 million baht from the end of 2024, following a strategic build-up to support projected sales growth in both domestic and international markets. However, a slowdown in orders from hospital-group customers was observed toward the end of the year, alongside adjusted delivery schedules from certain partners. This was driven by external uncertainties and logistical constraints, including flooding situations and export delays. As at December 31, 2025, the Group recognized an allowance for decline in value of inventories of 0.9 million baht (December 31, 2024: the allowance for decline in value of inventories was 0.7 million baht).
Other current assets increased by 8.5 million baht from the end of 2024, mainly from an increase in VAT credit carried forward.
Property, plant, and equipment rose by 625.5 million baht from the end of 2024, primarily due to the construction of a new production plant, which is approximately 93% complete, and the purchase of machinery to support the expansion of production capacity at the Ratchaburi plant.
Other non-current assets increased by 35.8 million baht from the end of 2024. This was mainly due to an increase in advance payments for the construction of a new production building and the purchase of machinery for both the new and existing plants.
Liabilities
Total liabilities of the Group were 686.8 million baht as at December 31, 2025, which increased by 134.9 million baht compared to 2024. The reasons were mainly from an increase in current liabilities and non-current liabilities by 124.2 million baht and 10.7 million baht, respectively, as follows:
Bank overdrafts and borrowings from financial institutions increased by 75.1 million baht to finance the Company's working capital needs. These loans carry interest rates ranging from 2.6% to 5.6% per annum.
Trade payables decreased by 24.5 million baht from the previous year. The reason was mainly due to a planned reduction in raw material and product procurement, in line with the strategy to enhance inventory management efficiency.
Other current payables increased by 82.9 million baht, primarily due to accrued dividend payments and outstanding payments for machinery that were not yet due at the end of the year.
Shareholders’ equity
Total shareholders’ equity decreased by 6.9 million baht, driven by the total comprehensive income for the year 2025 by 169.5 million baht, offset by a dividend announcement by 176.4 million baht during the year.
Debt Obligations & Off-Balance-Sheet Management
Assets & Liabilities Management: As at December 31, 2025, the cash cycle stood at 235.0 days, representing an increase from the end of the previous year. This was primarily driven by an increase in the average inventory period from 204.7 days to 219.3 days. Nevertheless, the Group remains committed to efficient working capital management. We successfully reduced the average collection period to 81.8 days and maintained an optimal average payment period of 66.1 days to mitigate any impact on overall liquidity.
Leverage Ratios: The debt-to-equity (D/E) ratio stood at 0.4 times, a slight increase from the end of last year. The proportion of loans from financial institutions to interest-bearing debt rose from 19.2% to 26.4%. This was primarily driven by an increase in current liabilities from dividends payable, as well as the management of credit facilities to support liquidity for business expansion. Nonetheless, the Company continues to maintain a healthy D/E ratio.
The interest coverage ratio, as at December 31, 2025, stood at 39.9 times, a significant improvement from 23.2 at the end of 2024. This was mainly due to a reduction in finance costs following the scheduled repayment of outstanding loans to financial institutions during the year.
Debt Securities with Financial Ratio Requirements
Debt Securities with Financial Ratio Requirements Issued?
No
Factors That May Affect Financial Condition
Factors or Incidents That May Materially Affect Financial Condition
1. External Factors
Industry Growth Trajectory: The pharmaceutical and healthcare industry is projected to grow annually. Key drivers include the aging society, the rise of Non-Communicable Diseases (NCDs), and environmental factors such as pollution and seasonal climate changes.
Government Policies: Support for healthcare accessibility through pharmacy networks and herbal medicine initiatives (NHSO) facilitates broader product distribution and market penetration.
Macroeconomic Risks: Geopolitical tensions, global economic volatility, and natural disasters remain challenges that could impact consumer purchasing power, logistics, and international patient volumes.
2. Internal Factors & Strategies
Capacity Expansion: The completion of production facilities and assets under construction in 2026 will enhance production capacity and operational efficiency, directly bolstering profitability.
Cost Optimization: The implementation of Solar Farm Phase 2 and the utilization of BOI tax incentives are expected to significantly reduce energy costs and corporate tax expenses.
Strategic Focus: The company will prioritize high-margin product groups and proactive working capital management to ensure financial discipline and sustainable shareholder returns amidst market volatility.

